Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders.

doi:10.1021/jm3006542

Paper

Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders.

Published Jul 27, 2012 · A. Mazurov, L. Miao, B. Bhatti

Journal of medicinal chemistry

Q1 SJR score

29

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

Diversification of essential nicotinic cholinergic pharmacophoric elements, i.e., cationic center and hydrogen bond acceptor, resulted in the discovery of novel potent α4β2 nAChR selective agonists comprising a series of N-acyldiazabicycles. Core characteristics of the series are an exocyclic carbonyl moiety as a hydrogen bond acceptor and endocyclic secondary amino group. These features are positioned at optimal distance and with optimal relative spatial orientation to provide near optimal interactions with the receptor. A novel potent and highly selective α4β2 nAChR agonist 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (56, TC-6683, AZD1446) with favorable pharmaceutical properties and in vivo efficacy in animal models has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions and is currently being progressed to phase 2 clinical trials as a treatment for Alzheimer's disease.

Study Snapshot

The novel 42 nAChR agonist 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446) shows potential as a treatment for cognitive deficits in

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders.

Sign up to use Study Snapshot

References

Nicotinic acetylcholine receptor ligands, a patent review (2006 – 2011)

Nicotinic acetylcholine receptor ligands, particularly for 42 or 7 subtypes, show promise for treating central nervous system disorders and influencing channel functionalities.

Ligand-binding domain of an α7-nicotinic receptor chimera and its complex with agonist

The crystal structure of an 7-nicotinic receptor chimera reveals molecular rearrangements and interactions that mediate agonist recognition and early steps in signal transduction, providing a template for drug design.

A convenient synthesis of 5-fluorofuran-2-carboxylic acid

This study successfully synthesized 5-fluorofuran-2-carboxylic acid in two steps with 56% total yield using potassium fluoride and catalytic tetraphenylphosphonium bromide in sulfolane at 140°C for 2 hours.

Identification of 9-fluoro substituted (-)-cytisine derivatives as ligands with high affinity for nicotinic receptors.

9-fluoro substituted (-)-cytisine derivatives show high affinity and selectivity for nicotinic receptors, with the size of the 9-position substituent being more important than electronic factors.

Nicotinic pharmacophore: The pyridine N of nicotine and carbonyl of acetylcholine hydrogen bond across a subunit interface to a backbone NH

Nicotinic pharmacophore complete, offering insights into designing new therapeutic agents targeting nicotine addiction-related receptors.

TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.

TC-5619, a selective alpha7 nicotinic receptor agonist, shows potential in treating schizophrenia symptoms and cognitive dysfunction, both alone and in combination with antipsychotics.

Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system

Nicotinic receptors are potential therapeutic targets for treating nervous-system disorders like Alzheimer's disease, schizophrenia, depression, and tobacco addiction.

Octahydropyrrolo[3,4-c]pyrrole: a diamine scaffold for construction of either alpha4beta2 or alpha7-selective nicotinic acetylcholine receptor (nAChR) ligands. Substitutions that switch subtype selectivity.

The diamine scaffold octahydropyrrolo[3,4-c]pyrrole allows for the construction of highly selective nicotinic acetylcholine receptor ligands, providing insights into differences in binding domains between alpha4beta2 and alpha7 receptor

Novel acetylcholine and carbamoylcholine analogues: development of a functionally selective alpha4beta2 nicotinic acetylcholine receptor agonist.

Compound 5a is a functionally selective alpha4beta2 nicotinic acetylcholine receptor agonist with minimal activity at alpha3beta4, alpha4, and alpha7 subtypes, making it a potential therapeutic agent for Alzheimer's disease.

Citations